Compare · GWPH vs KDMN
GWPH vs KDMN
Side-by-side comparison of GW Pharmaceuticals Plc (GWPH) and Kadmon Holdings, Inc. (KDMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GWPH and KDMN operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- KDMN carries a market cap of $1.67B.
- KDMN has more recent analyst coverage (3 ratings vs 0 for GWPH).
- Company
- GW Pharmaceuticals Plc
- Kadmon Holdings, Inc.
- Price
- $219.01-0.21%
- $9.49+0.11%
- Market cap
- -
- $1.67B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2013
- 2016
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 3
Kadmon Holdings, Inc.
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. Kadmon Holdings, Inc., was incorporated in 2010 and is headquartered in New York, New York.
Latest GWPH
- IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
- Jazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District Court
- Study Suggests Whole-Plant Medicinal Cannabis Could Be More Effective Than CBD In Epilepsy Treatment
- SEC Form 15-12B filed by GW Pharmaceuticals Plc
- SEC Form 4: Tovey Christopher J. returned 2,496 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: Cline Darren S returned 5,556 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4 filed by GRYSKA DAVID W
- SEC Form 4: Giacobello Scott M. returned 165,108 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: Secor Alicia returned 10,584 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
- SEC Form 4: Knappertz Volker returned 92,412 units of Ordinary Shares to the company, decreasing direct ownership by 100% to 0 units
Latest KDMN
- Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors
- Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
- SEC Form 15-12B filed by Kadmon Holdings, Inc.
- SEC Form EFFECT filed by Kadmon Holdings, Inc.
- SEC Form EFFECT filed by Kadmon Holdings, Inc.
- SEC Form 4: Flowers Cynthia Louise gifted 20,150 shares and returned $103,075 worth of shares to the company (10,850 units at $9.50), closing all direct ownership in the company
- SEC Form 4 filed by Cohen David E
- SEC Form 4 filed by Ryan John L
- SEC Form 4: Waksal Harlan returned $1,690,478 worth of shares to the company (177,945 units at $9.50), closing all direct ownership in the company
- SEC Form 4: Moss Gregory S. returned $167,874 worth of shares to the company (17,671 units at $9.50), closing all direct ownership in the company